港股创新药再度走高，恒生创新药ETF、港股创新药ETF、港股通创新药ETF涨超2%

Group 1 - The Hong Kong stock market for innovative drugs has seen significant gains, with companies like Bohan Bio rising over 17%, and other firms such as Sihuan Pharmaceutical and Sanofi Biotech also experiencing substantial increases [1] - Various ETFs related to innovative drugs have also performed well, with multiple funds rising over 2% and others over 1.5% [1][3] Group 2 - Recent updates from the National Healthcare Security Administration indicate that several new innovative drugs have been rapidly entering hospitals, with a focus on those included in the medical insurance directory by May 2025 [5][6] - Notable drugs showing fast hospital admission growth include those from Kangfang Biotech and Shanghai Yizhong, among others [6] Group 3 - Citigroup's research report highlights a significant increase in market interest in the healthcare sector, particularly in innovative drugs, with expectations for the CXO sector to gain attention due to improved fundamentals and attractive valuations [7] - The report also mentions that WuXi AppTec's revenue for fiscal year 2024 is projected to reach 39.24 billion RMB (approximately 5.4 billion USD), with a growth forecast of 10%-15% for 2025 [7] Group 4 - According to CICC's research, China's innovative drug sector is transitioning into a phase of gradual innovation, gaining international competitiveness [8] - The report emphasizes that the domestic innovative drug industry is expected to reach a turning point by 2025, shifting from capital-driven growth to profit-driven growth [8]